[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380794-105":59,"doc-detail-380794-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bone-metastatic-carcinoma-with-egfr-amplification-and-mutation-a-case-report-and-literature-review","Bone metastatic carcinoma with EGFR amplification and mutation - A case report and literature review","","Mutations in the epidermal growth factor receptor (EGFR) gene are common in non-small cell lung cancer but rare in other tumors; they are particularly uncommon in bone metastases from cancer of unknown primary (BMCUP), for which no specific treatment options have been established. A 72-year-old man with persistent right shoulder and back pain developed functional impairment, sleep disturbance, and no respiratory or gastrointestinal complaints. Genetic testing showed EGFR amplification and mutation, and therapy with osimertinib plus bisphosphonates controlled disease and improved symptoms for up to 11 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bone-metastatic-carcinoma-with-egfr-amplification-and-mutation-a-case-report-and-literature-review/380794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bone-metastatic-carcinoma-with-egfr-amplification-and-mutation-a-case-report-and-literature-review/380794.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition is reported in the case?","Question",{"text":112,"@type":113},"The document reports bone metastatic carcinoma from cancer of unknown primary (BMCUP) with EGFR amplification and mutation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What symptoms led to the patient’s presentation?",{"text":117,"@type":113},"A 72-year-old man had persistent right shoulder and back pain for two weeks, worsened over one day, with right upper arm functional limitations and disrupted nighttime sleep.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment and outcome were reported?",{"text":121,"@type":113},"The patient received osimertinib (80 mg once daily) with bisphosphonates; tumor-related symptoms significantly improved, with disease control lasting up to 11 months and substantial pain relief.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380794,1790742502,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \n Clinical Case Report   \nBone metastatic carcinoma with EGFR amplification and mutation  \nA case report and literature review  \nHong-Juan Du, MSa , Fang-Fang Chen, MSa , Yu Liu, MSa , Yu Zhou, BSb,*   \n\n| Abstract\u003Cbr>Rationale: Mutations in the epidermal growth factor receptor (EGFR) gene are highly prevalent in non-small cell lung cancer, while rare in other cancers. Primarily it’s hardly present in bone metastases from cancer of unknown primary (BMCUP) . Currently, no specific treatment options for bone metastases from unknown primary cancers exist.\u003Cbr>Patient concerns: The right shoulder and back pain of a 72-years-old man had been persistent for 2 weeks and had developed worse on 1 particular day. The right upper arm was compromised, which also hindered the arm’s ability to raise and flex, and nighttime sleep was impacted. After applying the analgesic patch externally, the symptoms did not improve. No coughing or sputum production, chest tightness, shortness of breath, acid reflux, belching, abdominal pain, distension, diarrhea, backache, hematuria, black or bloody feces, or other discomforts appeared over the course of the illness.\u003Cbr>Diagnoses: The patient had a particular type of bone metastases from primary cancers with genetic test results indicating EGFR amplification and mutation.\u003Cbr>Interventions: A third-generation tyrosine kinase inhibitors drug, oral Osimertinib 80 mg once a day with bisphosphonates antibone destruction treatment was performed on schedule.\u003Cbr>Outcomes: Following treatment, the patient’s tumor-related symptoms were significantly improved by controlling the disease for up to 11 months and providing great pain relief.\u003Cbr>Lesson: EGFR-based genetic testing has emerged as a key measure for targeted therapy in non-small cell lung cancer. However, there are fewer relevant studies for other tumor types like BMCUP. Combined with literature reviews and our report, we provide evidence that targeting EGFR mutations according to the “basket theory” for the treatment of BMCUP is effective. Abbreviations: BMCUP = bone metastases from cancer of unknown primary, CUP = cancer of unknown primary, EGFR = epidermal growth factor receptor, FDG = fludeoxyglucose, NSCLC = non-small cell lung cancer, TKI = tyrosine kinase inhibitor. |\n| --- |\n| Keywords: BMCUP, Case report, EGFR, osimertinib |\n\n1. Introduction  \nWe report the diagnosis and treatment of a case of bone metastasis from the unknown primary lesion with epidermal growth factor receptor (EGFR) amplification and mutation and combine it with a literature review to discuss it, and to provide reference and help for clinical diagnosis and treatment. The patient has provided written informed consent for the publication of this manuscript and any identifiable images or data.  \nCancer of unknown primary (CUP) is a generic term for a group of metastatic tumors that are histologically diagnosed as metastatic but whose primary anatomical site cannot be identified after examination, accounting for approximately 3% to 5% of all new cancers in humans. [1] Bone metastases from cancer of unknown primary (BMCUP) is a type of CUP with a poor overall prognosis, accounting for about 10% of CUP. BMCUP  \nThe authors have no funding and conflicts of interest to disclose.  \nThe datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.  \na Department of Oncology, Chongqing General Hospital, Chongqing, China, b Department of Respiration, Fuling People’s Hospital, Chongqing, China.  \n* Correspondence: Yu Zhou, Department of Respiration, Fuling People’s Hospital, No. 6 Mingkang Lane, Fuling District, Chongqing 408000, China (e-mail:  \n[caihongyu121130@163.com](caihongyu121130@163.com)).  \nis common in adults, with a median age of 65 to 90 years, and slightly more males than females. Patients with BMCUP usually have a poor prognosis, with a mean survival of 3 to 12 months. [2] N","cbCaibUBnE6CtDlU","https://ap.wps.com/l/cbCaibUBnE6CtDlU","pdf",545327,"English","# Abstract\n# Keywords\n# 1. Introduction\n# 2. Consent for publication\n# 3. Case report","[{\"question\":\"What condition is reported in the case?\",\"answer\":\"The document reports bone metastatic carcinoma from cancer of unknown primary (BMCUP) with EGFR amplification and mutation.\"},{\"question\":\"What symptoms led to the patient’s presentation?\",\"answer\":\"A 72-year-old man had persistent right shoulder and back pain for two weeks, worsened over one day, with right upper arm functional limitations and disrupted nighttime sleep.\"},{\"question\":\"What treatment and outcome were reported?\",\"answer\":\"The patient received osimertinib (80 mg once daily) with bisphosphonates; tumor-related symptoms significantly improved, with disease control lasting up to 11 months and substantial pain relief.\"}]","Bone metastatic carcinoma with EGFR amplification and mutation - A case report and literature review | PDF",1790242161]